---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-001336"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:46:04.965024+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics reports 2025 net loss of $66.5M; tovecimig PFS/OS data due in April

## Summary
- Net loss $66.5M ($0.42/share) vs $49.4M ($0.36/share) in 2024; R&D spend up 32% to $56.0M.
- Cash and marketable securities $209M as of Dec 31, 2025; expected runway into 2028.
- Tovecimig COMPANION-002 PFS/OS analyses expected in April 2026 after reaching 80% OS events.
- CTX-8371 expansion cohorts enrolling in TNBC and NSCLC; initial data expected Q2 2026.
- CTX-10726 IND cleared; Phase 1 enrolling in Q1 2026; Bing Gong promoted to CSO.

## SEC filing metadata
- accession: 0001171843-26-001336
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184326001336/0001171843-26-001336-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184326001336/f8k_030326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-001336
- JSON: https://secwatch.observer/filing/0001171843-26-001336.json
- Plain text: https://secwatch.observer/filing/0001171843-26-001336.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.